David Socks

David Socks is the Board Chair of Eleusis. In addition to his role at Eleusis, he is the CFO and CBO of Hillevax, as well as a Board Member of Phathom Pharmaceuticals (Nasdaq: PHAT), where he was the founding Chief Executive Officer through the company’s IPO. He previously served as a Venture Partner at Frazier Healthcare Partners, where he helped lead the firm’s company creation efforts, co-founding companies such as Arcutis (Nasdaq: ARQT), Passage Bio (Nasdaq: PASG) and Scout Bio. David has also served as an advisor to Prometheus Bioscience (Nasdaq: RXDX) and PvP Biologics (acquired by Takeda). Previously, he was co-founder, President and COO of Incline Therapeutics (acquired by the Medicines Company) and co-founder and Senior Vice President, Corporate Development and Strategy of Cadence Pharmaceuticals (Nasdaq: CADX; acquired by Mallinckrodt).

David holds a B.S. from Georgetown University and an M.B.A from Stanford University.